Numab Therapeutics AG
12Patents
12Active
12Granted
44Portfolio score
Filing activity: May 12, 2014 → Jan 29, 2022
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10077312B2 | CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases | Chemistry; Metallurgy | 3 | Active |
| US11236150B2 | Hetero-dimeric multi-specific antibody format | Chemistry; Metallurgy | 1 | Active |
| US12098203B2 | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | Chemistry; Metallurgy | 0 | Active |
| US10774140B2 | Anti-TNFα-antibodies and functional fragments thereof | Chemistry; Metallurgy | 0 | Active |
| US11365240B2 | Anti-HSA antibodies | Chemistry; Metallurgy | 0 | Active |
| US11427628B2 | Antibody frameworks | Chemistry; Metallurgy | 0 | Active |
| US11879005B2 | Hetero-dimeric multi-specific antibody format | Chemistry; Metallurgy | 0 | Active |
| US11421035B2 | Stable antibody variable domain framework combinations and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US11319371B2 | Anti-CD3 antibodies | Chemistry; Metallurgy | 0 | Active |
| US12209133B2 | Antibodies targeting CD137 and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US12077588B2 | Antibodies targeting PDL1 and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US12202911B2 | Multispecific antibody comprising CD137 binding domain and PDL1 binding domain | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.